BIOMAT Database Logo BIOMAT Database Logo

Human antibodies responsible for binding inhibition and polymerization inhibition of human immunodeficiency virus type 1 reverse transcriptase. 1996

F Odawara, and K Sano, and T Otake, and S Okubo, and T Nakano, and T Takasaki, and N Ueba, and H Misaki, and M Nakai
Department of Microbiology, Osaka Medical College, Japan.

Using a solid-phase non-radioisotopic (non-RI) reverse transcriptase (RT) assay, antibodies inhibiting human immunodeficiency virus type 1 (HIV-1) RT activity (RTI antibody) were investigated for their ability to inhibit binding of RT to a template-primer and DNA polymerization. The RTI antibody inhibited the binding of RT to the template-primer (BI antibody), and directly reacted with the RT-template-primer complex and inhibited enzymatic activity (PI antibody). The RTI antibody interfered with formation of the RT-template-primer complex suggesting that it recognized the antigenic site involved in template-primer binding of RT molecules. Since deoxynucleotide triphosphates (dNTPs) blocked inhibition of the RT activity by the PI antibody, the antigenic site recognized by the PI antibody may be closely related to the dNTP binding site. The seropositivities of the BI and PI antibodies were 84.6% and 91.2%, respectively, in HIV-1-infected individuals; healthy individuals, HTLV-I-positive individuals, autoimmune disease patients and leukemia patients were all seronegative. No significant correlation of residual RT activities was observed when BI and PI antibodies were compared (r = 0.688). It is possible that the epitopes recognized by the BI antibody differs from those recognized by the PI antibody. The assays described are able to detect BI and PI antibodies in the sera of HIV-1-infected individuals.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D012194 RNA-Directed DNA Polymerase An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49. DNA Polymerase, RNA-Directed,RNA-Dependent DNA Polymerase,Reverse Transcriptase,RNA Transcriptase,Revertase,DNA Polymerase, RNA Directed,DNA Polymerase, RNA-Dependent,RNA Dependent DNA Polymerase,RNA Directed DNA Polymerase

Related Publications

F Odawara, and K Sano, and T Otake, and S Okubo, and T Nakano, and T Takasaki, and N Ueba, and H Misaki, and M Nakai
Human Immunodeficiency Virus type 1 reverse transcriptase.
February 1996, Biological chemistry Hoppe-Seyler,
F Odawara, and K Sano, and T Otake, and S Okubo, and T Nakano, and T Takasaki, and N Ueba, and H Misaki, and M Nakai
Substrate inhibition of the human immunodeficiency virus type 1 reverse transcriptase.
July 1991, Proceedings of the National Academy of Sciences of the United States of America,
F Odawara, and K Sano, and T Otake, and S Okubo, and T Nakano, and T Takasaki, and N Ueba, and H Misaki, and M Nakai
Recombinant human antibodies against the reverse transcriptase of human immunodeficiency virus type-1.
May 2003, Biochimica et biophysica acta,
F Odawara, and K Sano, and T Otake, and S Okubo, and T Nakano, and T Takasaki, and N Ueba, and H Misaki, and M Nakai
The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase.
January 1992, The Journal of biological chemistry,
F Odawara, and K Sano, and T Otake, and S Okubo, and T Nakano, and T Takasaki, and N Ueba, and H Misaki, and M Nakai
Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations.
June 2006, Biochemistry,
F Odawara, and K Sano, and T Otake, and S Okubo, and T Nakano, and T Takasaki, and N Ueba, and H Misaki, and M Nakai
Inhibition of foamy virus reverse transcriptase by human immunodeficiency virus type 1 RNase H inhibitors.
July 2014, Antimicrobial agents and chemotherapy,
F Odawara, and K Sano, and T Otake, and S Okubo, and T Nakano, and T Takasaki, and N Ueba, and H Misaki, and M Nakai
Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
January 2004, Current topics in medicinal chemistry,
F Odawara, and K Sano, and T Otake, and S Okubo, and T Nakano, and T Takasaki, and N Ueba, and H Misaki, and M Nakai
Inhibition of human immunodeficiency virus type 1 reverse transcriptase by 3'-blocked oligonucleotide primers.
June 1992, Biochemical pharmacology,
F Odawara, and K Sano, and T Otake, and S Okubo, and T Nakano, and T Takasaki, and N Ueba, and H Misaki, and M Nakai
Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase.
January 1995, Methods in enzymology,
F Odawara, and K Sano, and T Otake, and S Okubo, and T Nakano, and T Takasaki, and N Ueba, and H Misaki, and M Nakai
Human immunodeficiency virus type 1 reverse transcriptase. Affinity labeling of the primer binding site.
November 1992, FEBS letters,
Copied contents to your clipboard!